Page 25 - AWA Vol.42-No.8 issue
P. 25
POULTRy
Neion Bio brings Barnwell Bio's biosurveillance into its egg-
based drug manufacturing flocks
Neion Bio, the New York company that
engineers hens to make biologics in
their eggs, will partner with Barnwell Bio
to use its avian biosurveillance technol-
ogy. Barnwell will track the health and
microbial environment of Neion's flocks
as Neion scales its Raptor manufacturing
platform.
The deal follows from how Neion makes
drugs. Its platform programs hens to ex-
press recombinant proteins, including
monoclonal antibodies, enzymes and
fusion proteins, directly in egg whites.
That swaps steel bioreactors for animals
and turns flock health into a manufac-
turing variable. In a conventional plant,
contamination is an event in a tank. In
Neion's, it is an event in a barn.
Neion argues the animal model also "Monitoring COVID-19 in wastewater of goods by up to 10 times and capital
brings something steel does not.
consistently produced valuable signal spending by up to 100 times against con-
"One of the advantages of the Raptor on how the virus was spreading weeks ventional manufacturing. Those figures
platform is that it can create a level of ahead of reported cases and hospitaliza- have not been independently shown.
redundancy in biologics manufacturing tions. At Barnwell Bio, we often identify
that is difficult to achieve with traditional elevated pathogen load in the barn en- The fit is simple on paper.
bioprocessing. We are not dependent vironment ahead of clinical signs, giving "Neion uses chickens to manufacture
on a single large bioreactor or manufac- producers early visibility into animal recombinant proteins. Barnwell provides
turing site. At the same time, the health health and the data they need to act," the intelligence needed to understand
of the flock remains critically important said Michael Rhys, cofounder and CEO and protect the health environment
to the productivity and reliability of the of Barnwell Bio. in which those chickens live," Kellari
system," said Dimi Kellari, cofounder Barnwell, in its January funding an- added.
and CEO of Neion Bio in an exclusive nouncement, put the cost of bird flu to
conversation with Synbiobeta. the US economy at $14 billion across Both companies are based in Manhat-
Barnwell works at the level of the pop- 2024 and 2025. Barnwell raised a $6 mil- tan, an unusual address for chicken bi-
ology, and a test of how far New York's
ulation rather than the bird. Instead of lion seed round in January led by Twelve
testing individual animals for named Below. Poultry is its starting market, with life sciences push reaches beyond ther-
pathogens, it sequences environmental swine, dairy and aquaculture named as apeutics and diagnostics. That push has
samples and, the company says, turns extensions. lost some institutional support. In June,
hundreds of thousands of data points The timing tracks Neion's own scale- Crain's New York Business reported that
into a microbiome fingerprint for each up. the city's economic development agency
facility. Barnwell says that fingerprint had cut its life sciences workforce, rais-
can flag a pathogen spike ahead of other "As Neion moves from platform devel- ing fears about the industry's growth.
methods. "We have been able to find un- opment toward larger-scale production, The mayor's office did not respond to a
usual pathogen loads in the environment biosecurity and flock health become request for comment on the partnership.
weeks ahead of clinical signs," said Mi- increasingly important. Barnwell al- For operators, the question is whether
chael Rhys, cofounder and CEO of Barn- ready has a system capable of provid- an animal-based process can offer the
well Bio. ing actionable information in real-world
poultry environments, so we are able to control that partners and regulators ex-
"Barnwell gives us a way to continu- incorporate that capability into our man- pect of a bioreactor. A biologics process
ously monitor the health environment ufacturing strategy now rather than hav- is defined by what it measures. Neion
around the birds, identify potential is- ing to develop it ourselves," said Kellari. says the first year is about building that
sues early, and take action before they record.
affect flock performance," said Dimi Kel- Neion, which SynBioBeta profiled in
lari, cofounder and CEO of Neion Bio. April, emerged from stealth in March "Over the next 12 months, our priority
with a co-development and supply is to integrate that monitoring into our
The approach comes straight from pan- agreement with an unnamed major operations, establish a baseline under-
demic surveillance. Barnwell says its pharmaceutical company covering up standing of the flock environment, and
founding team helped build the national to three monoclonal antibodies. It raised use the resulting data to support biose-
COVID-19 wastewater monitoring sys- about $11 million in seed funding led by curity, animal health, and ultimately man-
tem, and its January seed release names Caffeinated Capital, then a $23 million ufacturing performance," Kellari said.
cofounder and COO Casey McGinley as Series A in June, again led by Caffein-
part of that effort. ated. Neion says its approach can cut cost Circle 28 on enquiry card
Vol. 42 No. 8 23

